Viva Biotech HoldingsFRA:VB0 +5.84%42 3-Year ROIIC % is 6.92 as of Dec. 2025, which is 80% above its 10-year median of 3.84. GuruFocus rates FRA:VB0 with a GF Score™ of 42/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,319 Biotechnology companies, Viva Biotech Holdings ranks better than 59.21% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Viva Biotech Holdings's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 6.92%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Viva Biotech Holdings's 3-Year ROIIC % or its related term are showing as below:
FRA:VB0's 3-Year ROIIC % is ranked better than 59.21% of 1319
companies
in the Biotechnology industry
Industry Median: -4.44
vs FRA:VB0: 6.92
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Viva Biotech Holdings 3-Year ROIIC % Related Terms
Viva Biotech Holdings 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB0 vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's 3-Year ROIIC % falls into.
Viva Biotech Holdings's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 21.728888 (Dec. 2025) - 42.227 (Dec. 2022) )
/
( 737.433 (Dec. 2025) - 1077.858 (Dec. 2022) )
=
-20.498112
/
-340.425
=
6.02%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Viva Biotech Holdings (FRA:VB0) has a 3-Year ROIIC % of 6.92 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Viva Biotech Holdings and its competitors. This is 80% above median its historical median of 3.84. Over the past decade, Viva Biotech Holdings' 3-Year ROIIC % has ranged from 1.46 to 16.55. According to the industry distribution chart, Viva Biotech Holdings ranks #538 out of 1319 companies in the Biotechnology industry, placing it in the top 40.8%.
Is Viva Biotech Holdings' 3-Year ROIIC % too high?
Viva Biotech Holdings' current 3-Year ROIIC % of 6.92 is 80% above median its 10-year median of 3.84. Over the past 10 years, this metric has ranged from a low of 1.46 to a high of 16.55. Based on the distribution chart, Viva Biotech Holdings ranks #538 out of 1319 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Viva Biotech Holdings has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #538 out of 1319 companies for 3-Year ROIIC %. This puts Viva Biotech Holdings in the upper half of its industry. Historically, Viva Biotech Holdings' own 3-Year ROIIC % has ranged from 1.46 to 16.55 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Viva Biotech Holdings and its competitors. Viva Biotech Holdings's current 3-Year ROIIC % is 6.92, which is 80% above median its own 10-year median of 3.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.15 — trading 81.3% above its estimated fair value. The current 3-Year ROIIC % is 6.92, which is 80% above median its 10-year median of 3.84. Viva Biotech Holdings' overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current 3-Year ROIIC % is 6.92 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.15 is trading 81.3% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
3-Year ROIIC %: 6.92 (80% above median its 10-year median of 3.84)
GF Value™: €0.08 vs. price of €0.15 (81.3% above fair value)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
42GF Score
Get the complete analysis for FRA:VB0
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
